We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Alliance Pharma Plc (APH) Ordinary 1p

Sell:45.00p Buy:45.45p 0 Change: 0.55p (1.23%)
FTSE AIM 100:0.24%
Market closed Prices as at close on 1 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:45.00p
Buy:45.45p
Change: 0.55p (1.23%)
Market closed Prices as at close on 1 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:45.00p
Buy:45.45p
Change: 0.55p (1.23%)
Market closed Prices as at close on 1 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Alliance Pharma plc is a United Kingdom-based international consumer healthcare company. The principal activity of the Company is to act as a holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. Its segments include Consumer Healthcare brands and Prescription Medicines. Its Consumer Healthcare brands include the Kelo-Cote franchise, Amberen, Nizoral, MacuShield, Aloclair, Vamousse, and other consumer healthcare brands. Its Prescription Medicines include Hydromol, Flamma Franchise, Forceval and other prescription medicines. Its products include Aloclair Plus Gel, Aloclair Plus Spray, Aloclair Plus Mouthwash, Anbesol Adult Strength Gel, Anbesol Teething Gel, Anbesol Liquid, Atopiclair Cream, and Atopiclair Lotion. It holds marketing rights to around 80 consumer healthcare brands and prescription medicines, which are sold worldwide in more than 100 countries.

Contact details

Address:
Avonbridge House, Bath Road
CHIPPENHAM
SN15 2BB
United Kingdom
Telephone:
+44 (01249) 466966
Website:
https://www.alliancepharmaceuticals.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 12 September 2024 12/09/24
Trading Announcement 29 July 2024 29/07/24
AGM 29 July 2024 29/07/24
Annual report 19 June 2024 19/06/24
Final results 08 May 2024 08/05/24
Final results 23 April 2024 23/04/24
Final results 09 April 2024 09/04/24
Trading Announcement 29 January 2024 29/01/24

General stock information

EPIC:
APH
ISIN:
GB0031030819
Market cap:
£244.88 million
Shares in issue:
540.57 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE AIM 100,FTSE AIM All Share

Key personnel

  • Nick Sedgwick
    Chief Executive Officer, Executive Director
  • Andrew Franklin
    Chief Financial Officer, Executive Director
  • Chris Chrysanthou
    Group General Counsel, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.